• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation.更正：乌帕替尼在真实世界中治疗特应性皮炎的长期有效性和安全性：48周观察期的中期分析。
Am J Clin Dermatol. 2023 Nov;24(6):963-964. doi: 10.1007/s40257-023-00813-4. Epub 2023 Aug 19.
2
Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation.在真实环境中乌帕替尼治疗特应性皮炎的长期疗效和安全性：观察 48 周的中期分析。
Am J Clin Dermatol. 2023 Nov;24(6):953-961. doi: 10.1007/s40257-023-00798-0. Epub 2023 Jun 15.
3
Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults.度普利尤单抗治疗青少年及成人中重度特应性皮炎的真实世界疗效及耐受性。
Adv Ther. 2023 May;40(5):2509-2514. doi: 10.1007/s12325-023-02490-5. Epub 2023 Mar 21.
4
A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis.一项在日本开展的3期随机、多中心、双盲研究，旨在评估乌帕替尼联合外用皮质类固醇激素治疗中度至重度特应性皮炎青少年及成年患者的安全性（Rising Up）：一项24周中期分析。
JAAD Int. 2021 Dec 20;6:27-36. doi: 10.1016/j.jdin.2021.11.001. eCollection 2022 Mar.
5
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials.度普利尤单抗治疗中重度特应性皮炎的疗效和安全性：来自两项随机临床试验 MEASURE UP 1 和 MEASURE UP 2 的随访数据分析。
JAMA Dermatol. 2022 Apr 1;158(4):404-413. doi: 10.1001/jamadermatol.2022.0029.
6
Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: 2-Year Interim Results from the Phase 3 Rising Up Study.乌帕替尼治疗日本特应性皮炎的安全性和有效性：3期Rising Up研究的2年中期结果
Dermatol Ther (Heidelb). 2023 Jan;13(1):221-234. doi: 10.1007/s13555-022-00842-7. Epub 2022 Nov 19.
7
Efficacy and Treatment Satisfaction of Different Systemic Therapies in Children and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Real-World Study.不同全身治疗方法对中重度特应性皮炎儿童和青少年的疗效及治疗满意度：一项真实世界研究
J Clin Med. 2023 Feb 1;12(3):1175. doi: 10.3390/jcm12031175.
8
Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study.乌帕替尼治疗中重度特应性皮炎的有效性和安全性：一项多中心、前瞻性、真实世界、队列研究。
Drugs R D. 2022 Sep;22(3):245-252. doi: 10.1007/s40268-022-00396-1. Epub 2022 Aug 3.
9
Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry.乌帕替尼治疗特应性皮炎的日常实践经验，重点关注手部湿疹：来自BioDay注册研究的结果
Contact Dermatitis. 2023 May;88(5):351-362. doi: 10.1111/cod.14276. Epub 2023 Jan 19.
10
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results.乌帕替尼加局部皮质类固醇治疗特应性皮炎：第 52 周 AD Up 研究结果。
J Allergy Clin Immunol. 2022 Mar;149(3):977-987.e14. doi: 10.1016/j.jaci.2021.07.036. Epub 2021 Aug 14.

引用本文的文献

1
Mid-term effectiveness, safety, and potential predictors of response of upadacitinib in patients with moderate-to-severe atopic dermatitis: a multicenter observational retrospective study.乌帕替尼治疗中重度特应性皮炎患者的中期疗效、安全性及反应的潜在预测因素：一项多中心观察性回顾性研究
An Bras Dermatol. 2025 May-Jun;100(3):566-569. doi: 10.1016/j.abd.2024.10.009. Epub 2025 Apr 21.
2
Effectiveness and Safety of Upadacitinib for Adolescents with Atopic Dermatitis in a Real-World Setting.在真实环境中乌帕替尼治疗青少年特应性皮炎的疗效和安全性。
Clin Drug Investig. 2024 Aug;44(8):629-634. doi: 10.1007/s40261-024-01382-y. Epub 2024 Jul 16.

Correction to: Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation.

作者信息

Chiricozzi Andrea, Ortoncelli Michela, Schena Donatella, Gori Niccolò, Ferrucci Silvia Mariel, Babino Graziella, Napolitano Maddalena, Fargnoli Maria Concetta, Stingeni Luca, Rossi Mariateresa, Romanelli Marco, Balestri Riccardo, Pellegrino Michele, Parodi Aurora, Bertoldi Alberto Maria, Palazzo Giovanni, Antonelli Flaminia, Pitino Annalisa, Tripepi Giovanni, Fabbrocini Gabriella, Balato Anna, Marzano Angelo Valerio, Girolomoni Giampiero, Ribero Simone, Peris Ketty

机构信息

Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Largo A. Gemelli 8, 00168, Rome, Italy.

UOC di Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

出版信息

Am J Clin Dermatol. 2023 Nov;24(6):963-964. doi: 10.1007/s40257-023-00813-4. Epub 2023 Aug 19.

DOI:
10.1007/s40257-023-00813-4
PMID:37597128
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10570227/
Abstract
摘要